CAN-3110, an HSV-1 oncolytic viral immunotherapy candidate, has received FDA fast track designation for adult patients with recurrent high-grade glioma.
The FDA has granted fast track designation to aglatimagene besadenovec plus valacyclovir for use as a potential therapeutic option in patients with pancreatic ductal adenocarcinoma.
DJ MedSci Healthcare Holdings Limited Global Offering EQS Newswire / 17/04/2023 / 12:06 UTC+8 MedSci Healthcare Holdings Limited Global Offering Highlights of the Global Offering:
DJ MedSci Healthcare Holdings Limited Global Offering EQS Newswire / 17/04/2023 / 12:06 UTC+8 MedSci Healthcare Holdings Limited Global Offering Highlights of the Global Offering: